| Market Cap | 5.59M | P/E | - | EPS this Y | 89.10% | Ern Qtrly Grth | - |
| Income | -9.95M | Forward P/E | -1.18 | EPS next Y | 67.70% | 50D Avg Chg | 8.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -42.00% |
| Dividend | N/A | Price/Book | 0.61 | EPS next 5Y | - | 52W High Chg | -78.00% |
| Recommedations | 3.00 | Quick Ratio | 1.25 | Shares Outstanding | 2.69M | 52W Low Chg | 44.00% |
| Insider Own | 16.92% | ROA | -70.09% | Shares Float | 1.90M | Beta | 0.85 |
| Inst Own | 7.42% | ROE | -137.90% | Shares Shorted/Prior | 10.95K/24.61K | Price | 5.46 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 405,831 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 263,305 | Change | -5.04% |
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Dawson James | Neutral | Aug 3, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fisher Kenneth R | Chief Financial Offi.. Chief Financial Officer | Aug 26 | Buy | 1.0300 | 20,000 | 20,600 | 40,000 | 09/07/22 |
| Kinder Gordon Winston | Chief Financial Offi.. Chief Financial Officer | Mar 17 | Buy | 1.159 | 2,500 | 2,898 | 18,500 | 03/21/22 |
| Dey Svetlana | Director Director | Mar 17 | Buy | 1.183 | 10,000 | 11,830 | 10,000 | 03/21/22 |
| Wurth Douglas Clark | Director Director | Mar 17 | Buy | 1.178 | 40,000 | 47,120 | 2,286,349 | 03/18/22 |
| Wurth Douglas Clark | Director Director | Mar 16 | Buy | 1.09 | 60,000 | 65,400 | 2,246,349 | 03/17/22 |
| Kinder Gordon Winston | Chief Financial Offi.. Chief Financial Officer | Mar 14 | Buy | 0.96 | 16,000 | 15,360 | 16,000 | 03/16/22 |